Cochrane for Clinicians
Putting Evidence into Practice
Intranasal Corticosteroids for Acute Bacterial Rhinosinusitis
FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.
FREE PREVIEW. Purchase online access to read the full version of this article.
Am Fam Physician. 2014 Sep 1;90(5):286-287.
Author disclosure: No relevant financial affiliations.
Do intranasal corticosteroids, with or without antibiotics, hasten the resolution of symptoms of acute bacterial rhinosinusitis?
Compared with patients not treated with intranasal corticosteroids, those who receive them have greater improvement or resolution of symptoms at two to three weeks, regardless of whether antibiotics are used. In a single head-to-head study, patients taking intranasal corticosteroids alone fared slightly better than those taking antibiotics alone. Higher doses of intranasal corticosteroids work better than lower doses. (Strength of Recommendation: A, based on consistent, good-quality patient-oriented evidence.)
Although acute bacterial rhinosinusitis is usually self-limited, up to 98% of office visits for “sinusitis” lead to a prescription for an antibiotic. Yet, even when stricter criteria are used for making the diagnosis, antibiotics yield modest benefits.1
These authors evaluated the role of intranasal corticosteroids, with and without antibiotics, in the treatment of acute bacterial rhinosinusitis in children and adults. Intranasal corticosteroid agents used included fluticasone (Flonase), mometasone (Nasonex), and budesonide (Rhinocort). Four double-blind, placebo-controlled trials of almost 2,000 patients were reviewed, but only three of the trials were included in the meta-analysis because one study had methodologic flaws and a high drop-out rate. The primary outcome of symptom resolution or improvement was measured at 15 days in one study and at 21 days in the other studies.
In the study with the high drop-out rate, symptoms improved more rapidly with intra-nasal corticosteroids vs. placebo (approximately three to four days). Meta-analysis of the other three studies showed that patients using intranasal corticosteroids had a 73% chance of having symptom resolution or improvement vs. 66% of those using a placebo inhaler (relative risk = 1.11; 95% confidence interval, 1.04 to 1.18; number needed to treat [NNT] = 15). In one of the studies in which patients received high-dose mometasone (400 mcg), the NNT was 12.
Only one study compared intranasal corticosteroid monotherapy with antibiotic monotherapy. The intranasal corticosteroids–only group had a statistically significant improvement of 0.6 points on the 15-point mean symptom score when compared with the antibiotic-only group.
No major adverse effects were reported in the trials, and minor effects included epistaxis, headache, and nasal irritation.
The American Academy of Pediatrics updated its guidelines for management of acute bacterial rhinosinusitis in patients one to 18 years of age.2 Although the guidelines state that a three-day observation period is permissible before treatment with amoxicillin, no comment is made on the use of intranasal corticosteroids. The Infectious Diseases Society of America recommends saline irrigation and/or intranasal corticosteroids, especially in refractory cases or in patients with a history of allergic symptoms.3 Recommendations from the University of Michigan Health System state that intranasal corticosteroids are “likely to be effective.”4
The practice recommendations in this activity are available at http://summaries.cochrane.org/CD005149.
Zalmanovici Trestioreanu A, Yaphe J. Intranasal steroids for acute sinusitis. Cochrane Database Syst Rev. 2013;(12):CD005149.
REFERENCESshow all references
1. Ahovuo-Saloranta A, et al. Antibiotics for acute maxillary sinusitis in adults. Cochrane Database Syst Rev. 2014;(2):CD000243....
2. Wald ER, et al. American Academy of Pediatrics. Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years. Pediatrics. 2013;132(1):e262–e280.
3. Chow AW, et al. Infectious Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. Clin Infect Dis. 2012;54(8):e72–e112.
4. University of Michigan Health System. Acute rhinosinusitis in adults. Updated August 2011. http://www.med.umich.edu/1info/FHP/practiceguides/Rhino/rhino.pdf. Accessed April 1, 2014.
These are summaries of reviews from the Cochrane Library.
The series coordinator for AFP is Corey D. Fogleman, MD, Lancaster General Hospital Family Medicine Residency, Lancaster, Pa.
A collection of Cochrane for Clinicians published in AFP is available at http://www.aafp.org/afp/cochrane.
Copyright © 2014 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Oct 15, 2016
Access the latest issue of American Family Physician